Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Status:
Active, not recruiting
Trial end date:
2021-04-05
Target enrollment:
Participant gender:
Summary
This is a single arm phase II trial to assess efficacy and confirm safety of infusions of
anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory
symptoms,with or without confirmed interstitial COVID-19 pneumonia by chest Xray or CT. A
total of 29 eligible subjects will be enrolled to receive anti-SARS-CoV-2 plasma.Outcomes
will be compared to hospitalized controls with confirmed COVID-19 disease through
retrospective chart review.